ESTRO Multidisciplinary Management of Breast Cancer 2017

• 2,600 patients – in follow up • Tailor dose across breast according to risk of relapse • Uses complex IMRT & IGRT • Secondary endpoints of normal tissue toxicity will report 2018

IMPORT HIGH trial

2.4Gy

2.7Gy

3.2Gy

15 fractions